| Literature DB >> 35207395 |
Abstract
To evaluate safety of quick discharge after robotic radical hysterectomy (RRH) in a tertiary hospital which has the enhanced recovery after surgery (ERAS) protocol. Among 94 consecutive cervical cancer patients who had undergone RRH, operative outcomes and the rate of unexpected visit after surgery were analyzed retrospectively. Patients were categorized as a surgery-to-discharge time of ≤12 h (early discharge [ED]) or >12 h (late discharge [LD]). About 77% (n = 72) of analyzed 94 patients discharged within 12 h after RRH. The ED group had significant correlation with shorter duration for urinary catheter required, less operative blood loss, and less voiding difficulty after long-term follow up compared to the LD group. There was no difference of perioperative complications and unexpected visit between the two groups. Performing nerve sparing (NS) RRH was only independent predictor for ED (p = 0.043, hazard ratio for LD = 0.22, confidence interval = 0.05-0.95). In conclusion, the ED within 12 h after RRH was safe in the setting of ERAS protocol. The NS-RRH could avoid the delay of genitourinary function recovery after surgery which caused LD. It can become the reasonable clinical pathway to discharge early patients who undergo NS-RRH with ERAS protocol.Entities:
Keywords: cervical cancer; enhanced recovery; robotics
Year: 2022 PMID: 35207395 PMCID: PMC8874658 DOI: 10.3390/jcm11041122
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Pain management in the setting of ERAS protocol.
| Intraoperative | dexamethasone 12 mg IV |
| ketorolac 30 mg IV (do not give with renal insufficiency or elderly patients) | |
| Recovery room | oxycodone/acetaminophen 7.5/325 mg PO |
| acetaminophen 1 g IV | |
| morphine 2 mg IV for breakthrough pain | |
| ketorolac 30 mg IV if patients staying longer than 6 h | |
| Discharge | oxycodone/acetaminophen 7.5/325 mg PO q 6 h for 2 weeks |
IV, intravenous; PO, per oral.
Clinicopathologic characteristics.
| Early Discharge | Late Discharge | ||
|---|---|---|---|
| Number of Patients (%) | |||
| Age (years) | 48.8 ± 13.0 | 43.1 ± 12.4 | 0.065 |
| Body mass index (kg/m2) | 26.5 ± 4.9 | 28.2 ± 8.2 | 0.366 |
| Tumor stage | 0.477 | ||
| IB1 | 61 (84.7) | 20 (90.9) | |
| IB2 | 11 (15.3) | 2 (9.1) | |
| Tumor size (cm, IQR) | 2 (2) | 1.3 (3) | 0.102 |
| Histology | 0.787 | ||
| Squamous cell carcinoma | 39 (54.2) | 11 (50) | |
| Adenocarcinoma | 33 (45.8) | 10 (45.5) | |
| Tumor grade | 0.938 | ||
| Well differentiated | 22 (30.6) | 6 (27.3) | |
| Moderately differentiated | 35 (48.6) | 10 (45.5) | |
| Poorly differentiated | 15 (20.8) | 6 (27.3) | |
| Lymphovascular space invasion | 20 (27.8) | 3 (13.6) | 0.167 |
| Parametrium invasion | 2 (2.8) | 3 (13.6) | 0.082 |
| Lymph node metastases | 13 (18.1) | 3 (13.6) | 0.755 |
| Vaginal cuff margin involvement | 2 (2.8) | 0 | 1.000 |
IQR, interquartile range.
Operative outcomes.
| Early Discharge | Late Discharge | ||
|---|---|---|---|
| Number of Patients (%) | |||
| Nerve-sparing RH | 47 (66.2) | 4 (18.2) | <0.001 |
| Operating time (min) | 189.8 ± 56.1 | 210.0 ± 48.4 | 0.132 |
| Estimated blood loss (ml, IQR) | 100 (50) | 125 (100) | 0.004 |
| Number of lymph nodes retrieved | 28.0 ± 9.3 | 26.8 ± 11.2 | 0.633 |
| Days of urinary catheter required | 1 (21) | 39 (37) | <0.001 |
| <1 week | 44 (61.1) | 4 (18.2) | |
| 1–6 weeks | 25 (34.7) | 8 (36.4) | |
| >6 weeks | 3 (4.2) | 10 (45.5) | |
| Perioperative complications | |||
| Major | 1 (1.4) | 2 (9.1) | 0.138 |
| Minor | 13 (18.1) | 6 (27.3) | 0.362 |
| Visit to emergency room after discharge | 15 (20.8) | 5 (22.7) | 0.849 |
| Re-admission after discharge | 5 (6.9) | 3 (13.6) | 0.385 |
| Chronic symptoms 2 years after surgery | |||
| Voiding difficulty | 2 (2.8) | 4 (18.2) | 0.025 |
| Overactive bladder | 4 (5.6) | 2 (9.1) | 0.622 |
| Stress urinary incontinence | 1 (1.4) | 0 | 1.000 |
RH, radical hysterectomy; IQR, interquartile range.